Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
30.3M
-
Number of holders
-
45
-
Total 13F shares, excl. options
-
19.4M
-
Shares change
-
+176K
-
Total reported value, excl. options
-
$41.7M
-
Value change
-
+$374K
-
Number of buys
-
7
-
Number of sells
-
-2
-
Price
-
$2.15
Significant Holders of AN2 Therapeutics, Inc. - Common Stock (ANTX) as of Q2 2024
46 filings reported holding ANTX - AN2 Therapeutics, Inc. - Common Stock as of Q2 2024.
AN2 Therapeutics, Inc. - Common Stock (ANTX) has 45 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.4M shares
of 30.3M outstanding shares and own 64.12% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (5.55M shares), Octagon Capital Advisors LP (3.22M shares), Frazier Life Sciences Management, L.P. (2.09M shares), TCG Crossover Management, LLC (1.56M shares), CITADEL ADVISORS LLC (1.55M shares), JANUS HENDERSON GROUP PLC (1.22M shares), VANGUARD GROUP INC (1.04M shares), MILLENNIUM MANAGEMENT LLC (526K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (313K shares), and BlackRock Inc. (300K shares).
This table shows the top 45 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.